Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
This book chapter (2022) reviews the use of psilocybin in the treatment of addiction with a specific focus on smoking (tobacco use disorder, TUD). After exploring the historical use of psychedelics to treat addiction, modern research on the topic is reviewed. The anti-addiction properties of psychedelics differ but are consistent with the notion that the persisting positive behaviour change prompted by psychedelic therapy is due to the amplification of psychotherapeutic processes.
Authors
- Matthew Johnson
Published
Abstract
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about the ceremonial use of classic psychedelics and epidemiological studies that are consistent with anti-addiction efficacy. I review modern research using psilocybin in the treatment of alcohol use disorder and tobacco use disorder. Both lines of research show high success rates in preliminary studies. General anti-addiction efficacy across a variety of classes of addictive drugs is consistent with the notion that the persisting positive behaviour change prompted by psychedelic therapy is due to the amplification of psychotherapeutic processes. Future research should examine the classic psychedelic treatment of additional substance use disorders including for opioids, cocaine, methamphetamine, and cannabis, and other disorders broadly characterized as addictions (e.g., obesity, problem gambling, hypersexual disorder). Future research should also explore addiction treatments with other classic psychedelics including LSD, mescaline, DMT, 5-MeO-DMT, and yet-to-be-discovered compounds. Experimental research is also needed to test different protocols for the delivery of classic psychedelic therapy for addictions. Given the staggering societal costs of substance use disorders, including the mortality caused by tobacco smoking, it is critical that public funding be made available for scientists to follow up on promising early findings of classic psychedelics in addiction treatment. The costs and risks of not conducting such research are too great.
Research Summary of 'Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation'
Introduction
Johnson frames tobacco smoking as a major global public‑health problem with very high mortality and limited long‑term success for existing behavioural and pharmacological cessation aids. The introduction defines "classic psychedelics" as drugs whose primary mechanism is agonism at the 5‑HT2A receptor (for example psilocybin, LSD, mescaline, and DMT) and situates renewed interest in these compounds as potential anti‑addiction medicines given historical reports and recent pilot data. The paper sets out to review multiple lines of evidence relevant to the hypothesis that classic psychedelics can facilitate recovery from substance use disorders, with a special focus on psilocybin for tobacco smoking cessation. Johnson outlines the plan to cover mid‑twentieth century clinical research, anthropological and epidemiological studies, modern clinical trials for alcohol and tobacco use disorders, and to highlight future research priorities and gaps.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Author
- APA Citation
Johnson, M. W. (2022). Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. Current Topics in Behavioral Neurosciences, 213-227. https://doi.org/10.1007/7854_2022_327
References (40)
Papers cited by this study that are also in Blossom
Akers, B. P., Ruiz, J. F., Piper, A. et al. · Economic Botany (2011)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Bonson, K. R. · Psychopharmacology (2017)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Doering-Silveira, E., Grob, C. S., Dobkin de Rios, M. et al. · Journal of Psychoactive Drugs (2005)
Dyck, E. · Social History of Medicine (2006)
Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)
Show all 40 referencesShow fewer
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Mangini, M. · Journal of Psychoactive Drugs (2011)
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Spitzer, M., Thimm, M., Hermle, L. et al. · Biological Psychiatry (1996)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. · ACS Pharmacology and Translational Science (2020)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Cited By (4)
Papers in Blossom that reference this study
Johnson, M. W., Naudé, G. P., Hendricks, P. S. et al. · JAMA Network Open (2026)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.